Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES). // International Journal of Lung Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000641?dgcid=rss_sd_all
Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES). International Journal of Lung Cancer. https://www.sciencedirect.com/science/article/pii/S3117504X26000641?dgcid=rss_sd_all
“Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES).” International Journal of Lung Cancer.
@article{article49836,
title = {Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES)},
journal = {International Journal of Lung Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000641?dgcid=rss_sd_all}
}